drugset / Trial / NCT01071096

Calcitonin Gene-related Peptide Levels in Chronic Migraine

NCT01071096

Phase 4 Completed 20 enrolled Cady, Roger, M.D. Allergan · collab
RandomizedCrossoverDouble-blindTreatment

Summary

Twenty patients will be enrolled in a 2-site, 7-month, double-blind study conducted to evaluate a reduction in headache days and attacks and calcitonin gene-related peptide (CGRP) levels in saliva following treatment with OnabotulinumtoxinA versus saline. Eligible patients will be randomized and receive injections of OnabotulinumtoxinA or Saline at Visit 1. Following 3 months plus a 1 month wash out, patients will receive cross-over injections at Visit 5. Patients will return for monthly visits and exit the study at Visit 8. Patients will collect saliva at monthly intervals and document in a daily headache diary throughout the study .

Timeline

Start
2010-06
Primary completion
2011-06
Completion
2011-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Botulinum toxin type A Protein / enzyme biologic 155 iu

Indications